Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma

    NEXT STORY
    Strengthening Your Immune System In a Pandemic: Reakiro Immunity Capsules
    PREV STORY
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology

    author_avatar
    NASDAQ Market News

    Global Electrostatic Disinfectant Sprayer Industry Analysis (2020-2025) and Impact of COVID-19

    author_avatar
    NASDAQ Market News

    NeuroMetrix Reports Q3 2018 Financial Results

    $3.8M GSK Milestone; Improved Operating PerformanceWALTHAM, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, ...

    author_avatar
    NASDAQ Market News